{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Second+line+chemotherapy&page=8",
    "query": {
      "intervention": "Second line chemotherapy",
      "page": 8
    },
    "page_size": 10
  },
  "pagination": {
    "page": 8,
    "page_size": 10,
    "total_count": 213,
    "total_pages": 22,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Second+line+chemotherapy&page=9&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Second+line+chemotherapy&page=7&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-18T22:53:21.715Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07869836",
      "title": "BL-M07D1 (Trastuzumab Brengitecan T-bren) vs Standard of Care Platinum-based Chemotherapy (PBC) for HER2-expressing Metastatic Urothelial Cancer After Progression on Anti-PD-(L)1-based Therapy",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Urothelial Cancer",
        "Metastatic Urothelial Cancer",
        "Bladder Cancer",
        "Bladder Cancer (BC)",
        "Bladder (Urothelial, Transitional Cell) Cancer",
        "Bladder (Urothelial, Transitional Cell) Cancer Metastatic or Unresectable",
        "Bladder Ca",
        "Bladder Cancer Recurrent",
        "Bladder Cancer Stage IV",
        "Urothelial Carcinoma Bladder",
        "Urothelial Carcinoma Recurrent",
        "Urothelial Carcinoma of the Urinary Bladder"
      ],
      "interventions": [
        {
          "name": "T-Bren, Dose level 1",
          "type": "DRUG"
        },
        {
          "name": "T-bren, Dose level 2",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine + Platinum Based Chemotherapy (Cisplatin or Carboplatin)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SystImmune Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 520,
      "start_date": "2026-11",
      "completion_date": "2029-12",
      "has_results": false,
      "last_update_posted_date": "2026-11-18",
      "last_synced_at": "2026-11-18T22:53:21.715Z",
      "location_count": 3,
      "location_summary": "Macon, Georgia • ‘Aiea, Hawaii • Fredericksburg, Virginia",
      "locations": [
        {
          "city": "Macon",
          "state": "Georgia"
        },
        {
          "city": "‘Aiea",
          "state": "Hawaii"
        },
        {
          "city": "Fredericksburg",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07869836"
    },
    {
      "nct_id": "NCT00149396",
      "title": "Safety & Efficacy of NV1020 in Colorectal Cancer Metastatic to the Liver",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Colorectal Cancer",
        "Liver Neoplasms"
      ],
      "interventions": [
        {
          "name": "NV1020",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "MediGene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2004-07",
      "completion_date": "2008-12",
      "has_results": true,
      "last_update_posted_date": "2018-04-24",
      "last_synced_at": "2026-11-18T22:53:21.715Z",
      "location_count": 5,
      "location_summary": "San Diego, California • Boston, Massachusetts • Pittsburgh, Pennsylvania + 2 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00149396"
    },
    {
      "nct_id": "NCT03391466",
      "title": "Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)"
      ],
      "interventions": [
        {
          "name": "Axicabtagene Ciloleucel",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Platinum-containing Salvage Chemotherapy",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Kite, A Gilead Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 359,
      "start_date": "2018-01-25",
      "completion_date": "2024-11-25",
      "has_results": true,
      "last_update_posted_date": "2025-12-01",
      "last_synced_at": "2026-11-18T22:53:21.715Z",
      "location_count": 30,
      "location_summary": "Gilbert, Arizona • Phoenix, Arizona • La Jolla, California + 24 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03391466"
    },
    {
      "nct_id": "NCT07225270",
      "title": "Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Platinum-sensitive Ovarian Cancer",
        "PSOC"
      ],
      "interventions": [
        {
          "name": "Rina-S",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genmab",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 544,
      "start_date": "2026-04-03",
      "completion_date": "2030-05",
      "has_results": false,
      "last_update_posted_date": "2026-11-16",
      "last_synced_at": "2026-11-18T22:53:21.715Z",
      "location_count": 16,
      "location_summary": "Sacramento, California • Hartford, Connecticut • Miami, Florida + 13 more",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "New Port Richey",
          "state": "Florida"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07225270"
    },
    {
      "nct_id": "NCT04743661",
      "title": "131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Medulloblastoma",
        "Recurrent Ependymoma"
      ],
      "interventions": [
        {
          "name": "Irinotecan",
          "type": "DRUG"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "Omburtamab I-131",
          "type": "DRUG"
        },
        {
          "name": "Liothyronine",
          "type": "DRUG"
        },
        {
          "name": "SSKI",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Antipyretic",
          "type": "DRUG"
        },
        {
          "name": "Antihistamine",
          "type": "DRUG"
        },
        {
          "name": "anti-emetics",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pediatric Brain Tumor Consortium",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 62,
      "start_date": "2022-04-04",
      "completion_date": "2027-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-07-28",
      "last_synced_at": "2026-11-18T22:53:21.715Z",
      "location_count": 3,
      "location_summary": "Los Angeles, California • New York, New York • Cincinnati, Ohio",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04743661"
    },
    {
      "nct_id": "NCT06796543",
      "title": "Targeted Oligometastatic Radiation in Pediatric and Young Adult Patients With Soft Tissue and Bone Sarcoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Metastatic Sarcoma",
        "Radiation Therapy Patient",
        "Ewing Sarcoma",
        "Rhabdomyosarcoma"
      ],
      "interventions": [
        {
          "name": "Consolidative radiation therapy (cRT)",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "RADIATION"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "39 Years",
        "sex": "ALL",
        "summary": "Up to 39 Years"
      },
      "enrollment_count": 70,
      "start_date": "2025-03-25",
      "completion_date": "2030-03",
      "has_results": false,
      "last_update_posted_date": "2026-07-13",
      "last_synced_at": "2026-11-18T22:53:21.715Z",
      "location_count": 3,
      "location_summary": "Washington D.C., District of Columbia • Baltimore, Maryland • Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06796543"
    },
    {
      "nct_id": "NCT04437485",
      "title": "eIMPACT-DM Pilot Trial: Depression Treatment to Reduce Diabetes Risk",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Depression",
        "Major Depressive Disorder",
        "Dysthymic Disorder",
        "Depressive Symptoms",
        "Type 2 Diabetes",
        "PreDiabetes",
        "Insulin Resistance"
      ],
      "interventions": [
        {
          "name": "Good Days Ahead (GDA)",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Problem Solving Treatment in Primary Care (PST-PC)",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Antidepressant Medications",
          "type": "DRUG"
        },
        {
          "name": "Active Control",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Indiana University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 46,
      "start_date": "2020-10-14",
      "completion_date": "2022-08-29",
      "has_results": true,
      "last_update_posted_date": "2023-11-02",
      "last_synced_at": "2026-11-18T22:53:21.715Z",
      "location_count": 1,
      "location_summary": "Indianapolis, Indiana",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04437485"
    },
    {
      "nct_id": "NCT01767155",
      "title": "Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Endometrial Cancer"
      ],
      "interventions": [
        {
          "name": "AEZS-108 / zoptarelin doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "doxorubicin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AEterna Zentaris",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 511,
      "start_date": "2013-04",
      "completion_date": "2017-01-30",
      "has_results": true,
      "last_update_posted_date": "2018-07-31",
      "last_synced_at": "2026-11-18T22:53:21.715Z",
      "location_count": 28,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • Orange, California + 24 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Hartford",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01767155"
    },
    {
      "nct_id": "NCT04697628",
      "title": "Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cervical Cancer"
      ],
      "interventions": [
        {
          "name": "tisotumab vedotin",
          "type": "DRUG"
        },
        {
          "name": "topotecan",
          "type": "DRUG"
        },
        {
          "name": "vinorelbine",
          "type": "DRUG"
        },
        {
          "name": "gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "irinotecan",
          "type": "DRUG"
        },
        {
          "name": "pemetrexed",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Seagen, a wholly owned subsidiary of Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 502,
      "start_date": "2021-02-22",
      "completion_date": "2026-01-15",
      "has_results": true,
      "last_update_posted_date": "2026-02-24",
      "last_synced_at": "2026-11-18T22:53:21.715Z",
      "location_count": 53,
      "location_summary": "Glendale, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 28 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04697628"
    },
    {
      "nct_id": "NCT03645928",
      "title": "Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Melanoma",
        "Squamous Cell Carcinoma of the Head and Neck",
        "Non-small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Lifileucel",
          "type": "BIOLOGICAL"
        },
        {
          "name": "LN-145",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "LN-145-S1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ipilimumab",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab-relatlimab",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Nab paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Pemetrexed",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Iovance Biotherapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 225,
      "start_date": "2019-05-07",
      "completion_date": "2026-02-20",
      "has_results": false,
      "last_update_posted_date": "2026-05-15",
      "last_synced_at": "2026-11-18T22:53:21.715Z",
      "location_count": 20,
      "location_summary": "La Jolla, California • Los Angeles, California • Denver, Colorado + 15 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03645928"
    }
  ]
}